**SINGAPORE** - A transformative chapter in cancer therapy has been authored with the completion of the world's largest immunotherapy clinical trial focused on solid tumors, including the notoriously challenging nasopharyngeal cancer (NPC). Despite the trial concluding without demonstrating significant overall survival benefits—a central benchmark in cancer studies—the insights gained from this groundbreaking research are anticipated to reshape the landscape of precision immunotherapy.

Named the Vance trial, this extensive multinational initiative was directed by Singapore’s esteemed clinician-scientist, Professor Toh Han Chong. It stands as the largest completed examination of T-cell therapy for any solid tumor to date. Professor Toh expressed pride in the achievement, calling it a “made-in-Singapore triumph” and praising the remarkable collaborative efforts by his team and local biotech companies in producing targeted T-cells for the trial.

Understanding Nasopharyngeal Cancer (NPC)